vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and JOINT Corp (JYNT). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $15.2M, roughly 1.4× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -373.3%, a 379.8% gap on every dollar of revenue. JOINT Corp produced more free cash flow last quarter ($334.7K vs $-72.3M).
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
AUTL vs JYNT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $15.2M |
| Net Profit | $-79.1M | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | -337.9% | 4.9% |
| Net Margin | -373.3% | 6.5% |
| Revenue YoY | — | 3.1% |
| Net Profit YoY | 3.6% | 5510.5% |
| EPS (diluted) | $-0.30 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.2M | ||
| Q3 25 | $21.2M | $13.4M | ||
| Q2 25 | $20.9M | $13.3M | ||
| Q1 25 | $9.0M | $13.1M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | $0 | $30.2M | ||
| Q2 24 | $0 | $30.3M | ||
| Q1 24 | $10.1M | $29.7M |
| Q4 25 | — | $991.1K | ||
| Q3 25 | $-79.1M | $855.0K | ||
| Q2 25 | $-47.9M | $93.4K | ||
| Q1 25 | $-70.2M | $967.8K | ||
| Q4 24 | — | $17.7K | ||
| Q3 24 | $-82.1M | $-3.2M | ||
| Q2 24 | $-58.3M | $-3.6M | ||
| Q1 24 | $-52.7M | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | -337.9% | 1.2% | ||
| Q2 25 | -292.6% | -8.6% | ||
| Q1 25 | -726.3% | -5.2% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | -5.9% | ||
| Q1 24 | -384.1% | -1.4% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | -373.3% | 6.4% | ||
| Q2 25 | -229.0% | 0.7% | ||
| Q1 25 | -781.1% | 7.4% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | -10.5% | ||
| Q2 24 | — | -11.9% | ||
| Q1 24 | -522.1% | 3.2% |
| Q4 25 | — | $0.06 | ||
| Q3 25 | $-0.30 | $0.06 | ||
| Q2 25 | $-0.18 | $0.01 | ||
| Q1 25 | $-0.26 | $0.06 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-0.31 | $-0.21 | ||
| Q2 24 | $-0.22 | $-0.24 | ||
| Q1 24 | $-0.24 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $15.1M |
| Total Assets | $661.9M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $23.6M | ||
| Q3 25 | $86.1M | $29.7M | ||
| Q2 25 | $123.8M | $29.8M | ||
| Q1 25 | $95.8M | $21.9M | ||
| Q4 24 | — | $25.1M | ||
| Q3 24 | $657.1M | $20.7M | ||
| Q2 24 | $705.9M | $17.5M | ||
| Q1 24 | $758.5M | $18.7M |
| Q4 25 | — | $15.1M | ||
| Q3 25 | $265.5M | $22.7M | ||
| Q2 25 | $346.5M | $23.2M | ||
| Q1 25 | $371.1M | $22.8M | ||
| Q4 24 | — | $20.7M | ||
| Q3 24 | $477.0M | $20.5M | ||
| Q2 24 | $527.8M | $23.2M | ||
| Q1 24 | $582.0M | $26.2M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | $661.9M | $69.4M | ||
| Q2 25 | $721.0M | $73.2M | ||
| Q1 25 | $746.3M | $80.1M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | $827.5M | $79.6M | ||
| Q2 24 | $853.6M | $82.4M | ||
| Q1 24 | $901.4M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $1.8M |
| Free Cash FlowOCF − Capex | $-72.3M | $334.7K |
| FCF MarginFCF / Revenue | -341.2% | 2.2% |
| Capex IntensityCapex / Revenue | 20.8% | 9.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | $-67.9M | $1.8M | ||
| Q2 25 | $-72.8M | $868.6K | ||
| Q1 25 | $-75.6M | $-3.7M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | $-76.7M | $3.4M | ||
| Q2 24 | $-51.1M | $-973.5K | ||
| Q1 24 | $-40.5M | $2.8M |
| Q4 25 | — | $334.7K | ||
| Q3 25 | $-72.3M | $1.5M | ||
| Q2 25 | $-80.1M | $363.6K | ||
| Q1 25 | $-83.8M | $-4.0M | ||
| Q4 24 | — | $8.2M | ||
| Q3 24 | $-86.3M | $3.2M | ||
| Q2 24 | $-51.9M | $-1.2M | ||
| Q1 24 | $-41.0M | $2.4M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | -341.2% | 10.9% | ||
| Q2 25 | -382.6% | 2.7% | ||
| Q1 25 | -933.1% | -30.8% | ||
| Q4 24 | — | 55.9% | ||
| Q3 24 | — | 10.6% | ||
| Q2 24 | — | -4.1% | ||
| Q1 24 | -406.8% | 8.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | 20.8% | 2.4% | ||
| Q2 25 | 34.8% | 3.8% | ||
| Q1 25 | 91.8% | 2.5% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | 5.3% | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUTL
Segment breakdown not available.
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
